Pharmacokinetics of [14C]Abacavir, a Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitor, Administered in a Single Oral Dose to HIV-1-Infected Adults: a Mass Balance Study

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  1999-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.43.12.2855PMID 10582871PMCID PMC89576
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man

  2004cited by this paper
• Safety and Pharmacokinetics of Abacavir (1592U89) following Oral Administration of Escalating Single Doses in Human Immunodeficiency Virus Type 1-Infected Adults

  1999cited by this paper
• Abacavir: Absolute Bioavailability, Bioequivalence of Three Oral Formulations, and Effect of Food

  1999cited by this paper
• Single-Dose Pharmacokinetics and Safety of Abacavir (1592U89), Zidovudine, and Lamivudine Administered Alone and in Combination in Adults with Human Immunodeficiency Virus Infection

  1999cited by this paper
• Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions.

  1998cited by this paper
• Report of the NIH Panel To Define Principles of Therapy of HIV Infection*

  1998cited by this paper
• AIDS Dementia Complex Diagnosis and Drug Treatment Options

  1998influential reference
• Report of the NIH Panel to Define Principles of Therapy of HIV Infection and Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Vol. 47/No. RR-5.

  1998cited by this paper
• Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

  1997cited by this paper
• Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

  1997cited by this paper
• 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

  1997cited by this paper
• Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89

  1997influential reference
• Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

  1997cited by this paper
• Clinical Pharmacokinetics of Stavudine

  1997cited by this paper
• Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection.

  1997cited by this paper
• Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV

  1993cited by this paper
• 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.

  1993cited by this paper
• Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.

  1992cited by this paper
• Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides.

  1989cited by this paper

• An HIV-1 Reference Epitranscriptome

  2025cites this paper
• Clinical considerations on the use of antiretrovirals and renal impairment

  2025influential citation
• The anti-HIV drug abacavir stimulates β-catenin activity in osteoblast lineage cells

  2024cites this paper
• Comparison of Chemical and Electrochemical Approaches to Abacavir Oxidative Stability Testing

  2023cites this paper
• Anti-HIV Drugs Cause Mitochondrial Dysfunction in Monocyte-Derived Macrophages

  2022influential citation
• Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis

  2021cites this paper
• Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection

  2020cites this paper
• Mass spectrometric investigations into the brain delivery of abacavir, stavudine and didanosine in a rodent model

  2020cites this paper
• Bio-analytical Assay Methods used in Therapeutic Drug Monitoring of Antiretroviral Drugs-A Review

  2019cites this paper
• AN INSIGHT INTO THE MECHANISMS OF ABACAVIR INDUCED HYPERSENSITIVITY REACTIONS WITH A VIEW TO DESIGNING SAFER THERAPEUTICS.

  2018cites this paper
• Structural and Functional Consequences of HIV-1 Viral Protein Tat and Morphine Co-Exposure at the Blood-Brain Barrier

  2018cites this paper
• Treatment of HIV associated neurocognitive disorders

  2018cites this paper
• Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis

  2018cites this paper
• The challenge of polypharmacy in an aging population and implications for future antiretroviral therapy development.

  2017cites this paper
• Liabilities Associated with the Formation of "Hard" Electrophiles in Reactive Metabolite Trapping Screens.

  2017cites this paper
• Acyl glucuronide metabolites: Implications for drug safety assessment.

  2017cites this paper
• Clinical Drug-Drug Interaction Data: Effects of Antiretroviral Agents on Co-administered Drugs

  2016cites this paper
• Clinical Drug-Drug Interaction Data: Effects of Co-administered Drugs on Pharmacokinetics of Antiretroviral Agents

  2016cites this paper
• In Vitro Reaction Phenotyping and Drug Interaction Data

  2016cites this paper
• Role and modulation of drug transporters in HIV-1 therapy.

  2016cites this paper
• Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals

  2016cites this paper
• The Role of Metabolizing Enzymes and Transporters in Antiretroviral Therapy.

  2016cites this paper
• Pharmacokinetic and Pharmacodynamic Drug Interactions Associated with Antiretroviral Drugs

  2016cites this paper
• Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir.

  2015cites this paper
• Abacavir, an anti–HIV-1 drug, targets TDP1-deficient adult T cell leukemia

  2015cites this paper
• Lopinavir/Ritonavir plus Lamivudine and Abacavir or Zidovudine dose Ratios for Paediatric Fixed-Dose Combinations

  2015cites this paper
• Central Nervous System Penetration of Antiretroviral Drugs: Pharmacokinetic, Pharmacodynamic and Pharmacogenomic Considerations

  2015cites this paper
• Are circulating metabolites important in pharmacokinetic drug-drug interactions? A retroanalysis of clinical data.

  2015cites this paper
• Abacavir: una revisión actualizada sobre sus propiedades y aplicaciones

  2015cites this paper
• Pharmacokinetic and Pharmacodynamic Drug Interactions with Ethanol (Alcohol)

  2014cites this paper
• Abacavir forms novel cross-linking abacavir protein adducts in patients.

  2014cites this paper
• Pharmacokinetics and Pharmacodynamics of Antiretrovirals in the Central Nervous System

  2014cites this paper
• Role of CNS transporters in the pharmacotherapy of HIV-1 associated neurological disorders.

  2014cites this paper
• PharmGKB summary: abacavir pathway

  2014cites this paper
• Microvessel Endothelial Cells Antiretroviral Drugs in Human Brain Induction of P-Glycoprotein by

  2014cites this paper
• Bioactivation to an aldehyde metabolite--possible role in the onset of toxicity induced by the anti-HIV drug abacavir.

  2014cites this paper
• Oxidative bioactivation of abacavir in subcellular fractions of human antigen presenting cells.

  2013cites this paper
• Population pharmacokinetics of abacavir in infants, toddlers and children.

  2013cites this paper
• Monitoring abacavir bioactivation in humans: screening for an aldehyde metabolite.

  2013cites this paper
• Induction of P-Glycoprotein by Antiretroviral Drugs in Human Brain Microvessel Endothelial Cells

  2013cites this paper
• A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice

  2013cites this paper
• Abacavir Pharmacogenetics – From Initial Reports to Standard of Care

  2013cites this paper
• Development and validation of the first liquid chromatography-tandem mass spectrometry assay for simultaneous quantification of multiple antiretrovirals in meconium.

  2013cites this paper
• UDP‐Glucuronosyltransferases: Pharmacogenetics, Functional Characterization, and Clinical Relevance

  2012cites this paper
• Antiretroviral drug treatment of CNS HIV-1 infection.

  2012cites this paper
• Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.

  2012cites this paper
• CSF Penetration by Antiretroviral Drugs

  2012cites this paper
• Protein adducts from the anti-HIV drug abacavir - possible biomarkers of drug toxicity

  2012influential citation
• A general framework for multi-compartmental analysis of drug chemotherapy dynamics in human immunodeficiency virus type-1 infected individuals

  2012cites this paper
• Use of antineoplastic agents in cancer patients with HIV/AIDS

  2012cites this paper
• Reactive aldehyde metabolites from the anti-HIV drug abacavir: amino acid adducts as possible factors in abacavir toxicity.

  2011cites this paper
• Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

  2011cites this paper
• Twenty-six years of HIV science: an overview of anti-HIV drugs metabolism

  2011cites this paper
• Molecular Recognition of the Antiretroviral Drug Abacavir: Towards the Development of a Novel Carbazole-Based Fluorosensor

  2011cites this paper
• Overton's Rule Helps To Estimate the Penetration of Anti-Infectives into Patients' Cerebrospinal Fluid

  2011cites this paper
• antiinfectives into patientscerebrospinal fluid

  2011cites this paper
• Synthesis and sensing properties of a new carbazole fluorosensor for detection of abacavir

  2010cites this paper
• Penetration of Drugs through the Blood-Cerebrospinal Fluid/Blood-Brain Barrier for Treatment of Central Nervous System Infections

  2010cites this paper
• Abacavir/lamivudine combination in the treatment of Hiv: a review

  2010cites this paper
• Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25 years after zidovudine.

  2010cites this paper
• Abacavir/lamivudine combination in the treatment of HIV: a review

  2010cites this paper
• HIV-1-Associated Neurocognitive Disorders in the HAART Era

  2009cites this paper
• Abacavir Pharmacokinetics During Chronic Therapy in HIV‐1‐Infected Adolescents and Young Adults

  2009cites this paper
• Metabolism of Antiviral Nucleosides and Nucleotides

  2009cites this paper
• Lopinavir Cerebrospinal Fluid Steady-State Trough Concentrations in HIV-Infected Adults

  2009cites this paper
• Darunavir Concentrations in Cerebrospinal Fluid and Blood in HIV-1–Infected Individuals

  2009cites this paper
• A Review of the Pharmacokinetics of Abacavir

  2008cites this paper
• P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution

  2007cites this paper
• What is the Objective of the Mass Balance Study? A Retrospective Analysis of Data in Animal and Human Excretion Studies Employing Radiolabeled Drugs

  2007influential citation
• Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine

  2007cites this paper
• Antiretroviral treatment of HIV-1 in the central nervous system

  2007cites this paper
• HIV Pharmacology: Barriers to the Eradication of HIV from the CNS

  2006cites this paper
• Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome.

  2006cites this paper
• Neuroactive Antiretroviral Drugs Do Not Influence Neurocognitive Performance in Less Advanced HIV-Infected Patients Responding to Highly Active Antiretroviral Therapy

  2006cites this paper
• Salvage Therapy With Abacavir and Other Reverse Transcriptase Inhibitors for Human Immunodeficiency-Associated Encephalopathy

  2006cites this paper
• Zidovudine, Lamivudine, and Abacavir

  2006cites this paper
• Antiretroviral therapy 2006: Pharmacology, applications, and special situations

  2006cites this paper
• Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites

  2006cites this paper
• Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

  2005cites this paper
• Sex differences in the pharmacologic effects of antiretroviral drugs: potential roles of drug transporters and phase 1 and 2 metabolizing enzymes.

  2005cites this paper
• Severe HIV-1 encephalitis and development of cerebral non-Hodgkin lymphoma in a patient with persistent strong HIV-1 replication in the brain despite potent HAART -- case report and review of the literature.

  2005cites this paper
• Once-Daily Abacavir in Place of Twice-Daily Administration

  2005cites this paper
• Choroid Plexus and Drug Therapy for AIDS Encephalopathy

  2005cites this paper
• Selected rare, noninfectious syndromes associated with HIV infection.

  2005cites this paper
• Cerebrospinal Fluid Viral Loads Reach Less than 2 Copies/ML in HIV-1-Infected Patients with Effective Antiretroviral Therapy

  2005cites this paper
• Factors affecting delivery of antiviral drugs to the brain

  2005cites this paper
• Population Pharmacokinetics of Abacavir in Plasma and Cerebrospinal Fluid

  2005cites this paper
• Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.

  2005cites this paper
• HPLC Methods for Recently Approved Pharmaceuticals

  2005cites this paper
• Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.

  2004cites this paper
• Anti-HIV drug distribution to the central nervous system.

  2004cites this paper
• Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen

  2004cites this paper
• Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders

  2004cites this paper
• Indinavir, Efavirenz, and Abacavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Subjects

  2003cites this paper
• Choroid plexus controls brain availability of anti-HIV nucleoside analogs via pharmacologically inhibitable organic anion transporters

  2003cites this paper
• Assessing the Efficacy of Highly Active Antiretroviral Therapy in the Brain

  2003cites this paper
• Clinical Implications of CNS Penetration of Antiretroviral Drugs

  2002cites this paper
• Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients

  2002cites this paper
• Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals

  2002cites this paper
• Abacavir hypersensitivity reaction.

  2002cites this paper